Ultragenyx to Present at Upcoming Investor Conferences
04 août 2020 08h31 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx Reports Second Quarter 2020 Financial Results and Corporate Update
30 juil. 2020 16h03 HE
|
Ultragenyx Pharmaceutical Inc.
Two U.S. FDA approvals in second quarter 2020 Second quarter 2020 total revenue of $61.7 million and Crysvita revenue in Ultragenyx territories of $32.4 million Maintains full year...
Ultragenyx to Host Conference Call for Second Quarter 2020 Financial Results and Corporate Update
24 juil. 2020 08h35 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., July 24, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx Announces U.S. Commercial Launch of Dojolvi™ (triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation Disorders
22 juil. 2020 08h35 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., July 22, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx Announces U.S. FDA Approval of Dojolvi™ (UX007/triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation Disorders
30 juin 2020 15h01 HE
|
Ultragenyx Pharmaceutical Inc.
Fourth U.S. FDA Approval for Ultragenyx in the Past Three Years – All for Rare Diseases which Previously Had No Approved Therapies Ultragenyx to Host Conference Call Today at 4:00 pm Eastern Time ...
Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita® (burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO)
18 juin 2020 13h16 HE
|
Ultragenyx Pharmaceutical Inc.
First Approved Therapy in the United States for Patients with TIO Who Cannot Undergo Surgical Removal of Tumors TIO is Second FDA-Approved Indication for Crysvita, Which is Also Approved for the...
Ultragenyx to Present at Upcoming Investor Conferences
28 mai 2020 08h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics
21 mai 2020 08h30 HE
|
Ultragenyx Pharmaceutical Inc.; Arcturus Therapeutics Holdings Inc.
NOVATO, Calif. and SAN DIEGO, May 21, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical, Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development and commercialization of novel...
Ultragenyx Announces Positive Data from Confirmatory Cohort of Phase 1/2 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
15 mai 2020 08h00 HE
|
Ultragenyx Pharmaceutical Inc.
All Patients in Cohort 3 Demonstrate Increased Time to Hypoglycemia and a Substantial Reduction in Cornstarch Use Introduction of Continuous Glucose Monitoring Reveals Early Transgene Expression and...
Ultragenyx Announces Positive Longer-term Results from First Three Cohorts of Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency
13 mai 2020 16h01 HE
|
Ultragenyx Pharmaceutical Inc.
All three patients in Cohort 3 now confirmed responders All three complete responders in the study remain clinically and metabolically stable after longer-term follow-up Ultragenyx to host ASGCT...